Quynh-Thu Le

List of Publications by Year
in descending order

165	11,384	46918 47	31759 101
papers	citations	h-index	g-index

169	169	169	12375
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nasopharyngeal carcinoma. Lancet, The, 2019, 394, 64-80.	6.3	1,667
2	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq0 0 0 rgBT /Overlock 10 T	6.3	879
3	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology, 2014, 110, 172-181.	0.3	585
4	The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology, 2019, 16, 669-683.	12.5	454
5	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3365-3373.	0.8	449
6	p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3930-3938.	0.8	313
7	Image-guided Hypo-fractionated Stereotactic Radiosurgery to Spinal Lesions. Neurosurgery, 2001, 49, 838-846.	0.6	298
8	Hypoxic gene expression and metastasis. Cancer and Metastasis Reviews, 2004, 23, 293-310.	2.7	287
9	Proposal for the 8th edition of the <scp>AJCC</scp>/<scp>UICC</scp> staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 546-558.	2.0	254
10	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and Oncology, 2018, 126, 3-24.	0.3	244
11	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2006, 12, 1507-1514.	3.2	237
12	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. Journal of Clinical Oncology, 2005, 23, 8932-8941.	0.8	233
13	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 156-164.	0.8	216
14	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 1143-1169.	0.8	216
15	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2018, 126, 25-36.	0.3	214
16	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). Journal of Clinical Oncology, 2021, 39, 956-965.	0.8	195
17	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	0.8	178
18	Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study. Journal of Clinical Oncology, 2011, 29, 2808-2814.	0.8	161

#	Article	IF	Citations
19	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
20	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2013, 19, 2208-2215.	3.2	149
21	Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1046-1054.	0.4	145
22	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 3307-3315.	2.0	125
23	Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10756-10761.	3.3	121
24	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2007, 69, 167-175.	0.4	111
25	A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research, 2005, 11, 5700-5707.	3.2	99
26	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.4	96
27	Galectin-1â€“driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. Journal of Clinical Investigation, 2019, 129, 5553-5567.	3.9	94
28	Treatment of maxillary sinus carcinoma. Cancer, 1999, 86, 1700-1711.	2.0	93
29	Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	85
30	Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 52-58.	1.1	83
31	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 568-576.	0.4	75
32	Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 996-1001.	0.4	73
33	Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03. Journal of Clinical Oncology, 2009, 27, 4281-4286.	0.8	72
34	Clinical biomarkers for hypoxia targeting. Cancer and Metastasis Reviews, 2008, 27, 351-362.	2.7	70
35	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 766-778.	0.4	70
36	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 872-884.	0.4	69

#	Article	IF	Citations
37	Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 89-99.	1.0	65
38	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. Clinical Cancer Research, 2014, 20, 5558-5569.	3.2	64
39	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. International Journal of Radiation Oncology Biology Physics, 2015, 91, 721-729.	0.4	64
40	Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4820-7.	3.3	63
41	Chemical Space Mimicry for Drug Discovery. Journal of Chemical Information and Modeling, 2017, 57, 875-882.	2.5	63
42	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1044-1052.	0.4	61
43	Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. Journal of Thoracic Oncology, 2006, 1, 802-9.	0.5	61
44	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. Journal of Clinical Oncology, 2020, 38, 2552-2557.	0.8	58
45	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute, 2019, 111, 655-663.	3.0	56
46	Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer, 2006, 106, 1940-1949.	2.0	54
47	Very highâ€energy electron (<scp>VHEE</scp>) beams in radiation therapy; Treatment plan comparison between <scp>VHEE</scp> , <scp>VMAT</scp> , and <scp>PPBS</scp>. Medical Physics, 2017, 44, 2544-2555.	1.6	54
48	Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 1578-1589.	0.8	50
49	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncology, The, 2021, 22, 727-736.	5.1	45
50	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncology, 2018, 4, 1073.	3.4	44
51	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 682-695.	0.4	42
52	Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. Nature Methods, 2022, 19, 759-769.	9.0	42
53	Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. International Journal of Radiation Oncology Biology Physics, 2003, 56, 375-383.	0.4	40
54	Age Disparity in Palliative Radiation Therapy Among Patients With Advanced Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 224-230.	0.4	40

#	Article	IF	Citations
55	Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004). Clinical Cancer Research, 2004, 10, 5418-5424.	3.2	39
56	Overview of Advances in Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3225-3226.	0.8	39
57	Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods. Journal of Clinical Microbiology, 2014, 52, 3802-3804.	1.8	36
58	Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Scientific Reports, 2016, 6, 31146.	1.6	36
59	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International Journal of Radiation Oncology Biology Physics, 2017, 97, 687-699.	0.4	35
60	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nature Communications, 2021, 12, 117.	5.8	34
61	Emerging Treatment Paradigms in Radiation Oncology. Clinical Cancer Research, 2015, 21, 3393-3401.	3.2	33
62	Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clinical Cancer Research, 2003, 9, 4287-95.	3.2	31
63	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2017, 97, 667-677.	0.4	30
64	Prognostic value of midtreatment FDGâ€PET in oropharyngeal cancer. Head and Neck, 2016, 38, 1472-1478.	0.9	29
65	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 338-343.	0.3	29
66	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.4	28
67	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Resultsâ€Medicare analysis. Cancer, 2018, 124, 4486-4494.	2.0	28
68	Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.. Journal of Clinical Oncology, 2018, 36, 6010-6010.	0.8	28
69	Identification of Doxorubicin as an Inhibitor of the IRE1Î±-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 2016, 6, 33353.	1.6	27
70	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiotherapy and Oncology, 2016, 119, 454-460.	0.3	27
71	Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. Journal of Nuclear Medicine, 2020, 61, 327-336.	2.8	27
72	In Vivo 1H Magnetic Resonance Spectroscopy of Lactate in Patients With Stage IV Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1151-1157.	0.4	26

#	Article	IF	Citations
73	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 617-625.	3.3	26
74	Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide. Journal of the National Cancer Institute, 2021, 113, 852-862.	3.0	26
75	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 294-301.e3.	1.1	25
76	Acridine Derivatives as Inhibitors of the IRE1Î±â€“XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 2055-2065.	1.9	24
77	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.3	24
78	Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6279-6284.	3.3	23
79	Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 942-952.	0.4	23
80	Long-Term Results of Radiation Therapy Oncology Group 9903: A Randomized Phase 3 Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2015, 91, 907-915.	0.4	22
81	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2016, 96, 362-371.	0.4	22
82	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer, 2022, 162, 221-236.	1.3	22
83	Galectin-1 links tumor hypoxia and radiotherapy. Glycobiology, 2014, 24, 921-925.	1.3	21
84	Botulinum Toxin Confers Radioprotection in Murine Salivary Glands. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1190-1197.	0.4	21
85	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 7078-7088.	3.2	21
86	Lysosomal trafficking mediated by Arl8b and BORC promotes invasion of cancer cells that survive radiation. Communications Biology, 2020, 3, 620.	2.0	21
87	Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. Oral Oncology, 2015, 51, 438-445.	0.8	20
88	Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombinationâ€“deficient cancer models. Journal of Clinical Investigation, 2021, 131, .	3.9	20
89	Identifying and Targeting Hypoxia in Head and Neck Cancer: A Brief Overview of Current Approaches. International Journal of Radiation Oncology Biology Physics, 2007, 69, S56-S58.	0.4	19
90	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. Practical Radiation Oncology, 2013, 3, 294-300.	1.1	19

#	Article	IF	Citations
91	Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chemical Biology, 2021, 28, 1206-1220.e6.	2.5	19
92	Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.. Journal of Clinical Oncology, 2019, 37, 6073-6073.	0.8	19
93	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncology, 2019, 95, 106-114.	0.8	18
94	Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. Cancer, 2019, 125, 704-711.	2.0	18
95	Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. Seminars in Radiation Oncology, 2009, 19, 53-62.	1.0	16
96	A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. Oral Oncology, 2015, 51, 1132-1137.	0.8	16
97	Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?. Oral Oncology, 2018, 86, 19-24.	0.8	16
98	Resection following concurrent chemotherapy and high-dose radiation for stage IIIA nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1331-1345.e1.	0.4	16
99	Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. British Journal of Cancer, 2021, 124, 604-615.	2.9	16
100	Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Network Open, 2021, 4, e2110438.	2.8	15
101	Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.. Journal of Clinical Oncology, 2019, 37, 6065-6065.	0.8	15
102	Î²-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging. Journal of Nuclear Medicine, 2015, 56, 1458-1464.	2.8	14
103	Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy. Laryngoscope, 2016, 126, 1977-1980.	1.1	14
104	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limitedâ€stage small cell lung cancer in elderly patients versus younger patients. Cancer, 2019, 125, 382-390.	2.0	14
105	Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. Radiotherapy and Oncology, 2021, 156, 201-208.	0.3	14
106	A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.. Journal of Clinical Oncology, 2018, 36, 6050-6050.	0.8	12
107	Palliative Radiation Before Hospice: The Long and the Short of It. Journal of Pain and Symptom Management, 2014, 48, 1070-1079.	0.6	11
108	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1708-1709.	0.8	11

#	Article	IF	Citations
109	Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach. International Journal of Radiation Oncology Biology Physics, 2017, 97, 849-857.	0.4	11
110	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	2.0	11
111	The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-Î°B signaling. Science Advances, 2022, 8, eabh2445.	4.7	10
112	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. Journal of Neurological Surgery, Part B: Skull Base, 2023, 84, 307-319.	0.4	10
113	Nonsurgical Therapy for Stages I and II Nonâ€“Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 237-261.	0.9	9
114	Evaluation of a metal artifact reduction technique in tonsillar cancer delineation. Practical Radiation Oncology, 2012, 2, 27-34.	1.1	9
115	Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 775-783.	0.4	9
116	Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition. Cancers, 2019, 11, 1192.	1.7	9
117	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. Clinical Cancer Research, 2020, 26, 2972-2985.	3.2	9
118	The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC).. Journal of Clinical Oncology, 2015, 33, 6003-6003.	0.8	9
119	Nasopharyngeal and Oropharyngeal Carcinomas: Target Delineation, Therapy Delivery and Stereotactic Boost Procedures with Intensity-Modulated/ Image-Guided Radiation Therapy. , 2007, 40, 208-231.		8
120	The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited. Cancer, 2017, 123, 12-16.	2.0	8
121	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1Î±â€“XBP1 Activation. Molecular Cancer Research, 2018, 16, 745-753.	1.5	8
122	Costâ€effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. Otolaryngology - Head and Neck Surgery, 2019, 161, 82-90.	1.1	8
123	Rab27b contributes to radioresistance and exerts a paracrine effect via epiregulin in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa091.	0.4	8
124	p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC).. Journal of Clinical Oncology, 2013, 31, 6007-6007.	0.8	8
125	Flexible radioluminescence imaging for FDGâ€guided surgery. Medical Physics, 2016, 43, 5298-5306.	1.6	7
126	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. Oral Oncology, 2017, 71, 180-183.	0.8	7

#	Article	IF	Citations
127	An International Consensus on the Design of Prospective Clinicalâ€“Translational Trials in Spatially Fractionated Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100866.	0.6	7
128	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	6
129	Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma. Laryngoscope, 2020, 130, E598-E604.	1.1	6
130	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores â€“ A pooled analysis of RTOG 0129 and 0522. Oral Oncology, 2021, 116, 105241.	0.8	6
131	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers, 2021, 13, 2882.	1.7	6
132	NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2019, 37, 6023-6023.	0.8	6
133	Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. International Journal of Radiation Oncology Biology Physics, 2022, 113, 787-795.	0.4	6
134	JUPITERâ€02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. Cancer Communications, 2022, 42, 56-59.	3.7	6
135	Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.. Journal of Clinical Oncology, 2015, 33, 6011-6011.	0.8	5
136	The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. Cancer Research Communications, 2022, 2, 725-738.	0.7	5
137	Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma. Head and Neck, 2020, 42, 3188-3196.	0.9	4
138	A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).. Journal of Clinical Oncology, 2017, 35, TPS6097-TPS6097.	0.8	4
139	Radiographic Extranodal Extension in Human Papillomavirus-Associated Oropharyngeal Carcinoma: Can it Help Tailor Treatment?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1028-1029.	0.4	3
140	18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002.. Journal of Clinical Oncology, 2020, 38, 6563-6563.	0.8	3
141	Risk stratification after recurrence of human papillomavirus (HPV) â€related and nonâ€HPV â€related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	0.9	3
142	The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2012, 7, 381-394.	1.5	2
143	Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure. Journal of Radiation Oncology, 2014, 3, 49-56.	0.7	2
144	Individualizing treatment for patients with nasopharyngeal cancer. Cancer, 2015, 121, 2671-2673.	2.0	2

#	Article	IF	Citations
145	In Reply to Zoto Mustafayev and Ozyar. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1307.	0.4	2
146	The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience.. Journal of Clinical Oncology, 2014, 32, 6025-6025.	0.8	2
147	Effect of the extent of lymph node dissection on overall survival in patients treated for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6075-6075.	0.8	2
148	Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.. Journal of Clinical Oncology, 2016, 34, 6024-6024.	0.8	2
149	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.. Journal of Clinical Oncology, 2019, 37, 6010-6010.	0.8	2
150	Acceler-Dated Fractionation: The End of the Era of the Large, â€œOne Size Fits Allâ€•Trial for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 7-9.	0.4	1
151	Focus on the Number of Radiation Oncology Trials or on Clinical Relevanceâ€”Reply. JAMA Oncology, 2018, 4, 1791.	3.4	1
152	Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216.. Journal of Clinical Oncology, 2013, 31, TPS6099-TPS6099.	0.8	1
153	Feasibility of optimizing intensityâ€modulated radiation therapy plans based on measured mucosal dose adjacent to dental fillings and toxicity outcomes. Journal of Applied Clinical Medical Physics, 2018, 19, 444-452.	0.8	0
154	In Regard to Beadle and Anderson. International Journal of Radiation Oncology Biology Physics, 2018, 102, 229-230.	0.4	0
155	The role of Glial cell derived neurotrophic factor in head and neck cancer. PLoS ONE, 2020, 15, e0229311.	1.1	0
156	Reply to A. J. Cmelak et al and B. Kalra et al. Journal of Clinical Oncology, 2021, 39, 2734-2735.	0.8	0
157	Racial inequality with radiation oncology referral and treatment in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 470-470.	0.8	0
158	Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6077-6077.	0.8	0
159	Outcomes of elderly patients treated for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6076-6076.	0.8	0
160	Prognostic value of mid-treatment total lesion glycolysis in p16+ oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, 6047-6047.	0.8	0
161	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. Journal of Clinical Oncology, 2016, 34, 8510-8510.	0.8	0
162	Comments on the Publication by Corkum etÂal on â€œDoes 5 + 5Âmm Equal Better Radiation Treatment Plans in Head and Neck Cancers?â€• Advances in Radiation Oncology, 2020, 5, 140-141.	0.6	0

#	Article	IF	Citations
163	Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.4	0
164	De-escalating elective nodal irradiation for nasopharyngeal carcinoma. Lancet Oncology, The, 2022, 23, 441-443.	5.1	0
165	Aldehyde dehydrogenase 3A1 deficiency leads to mitochondrial dysfunction and impacts salivary gland stem cell phenotype. , 2022, 1, .		0